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We describe a case of twins with sporadic Gorlin syn-
drome. Both twins had common Gorlin syndrome fea-
tures including calcification of the falx cerebri, multiple jaw 
keratocysts, and multiple basal cell carcinomas, but with 
different expressivity. One brother also had benign testic-
ular mesothelioma. We propose this tumor type as a pos-
sible new feature of Gorlin syndrome. Gorlin syndrome is a 
rare autosomal dominant disorder characterized by both 
developmental abnormalities and cancer predisposition, 
with variable expression of various developmental abnor-
malities and different types of tumors. The syndrome is pri-
marily caused by mutations in the Patched 1 (PTCH1) gene, 
although rare mutations of Patched 2 (PTCH2) or Suppres-
sor of Fused (SUFU) genes have also been found. Neither 
founder mutations nor hot spot locations have been de-
scribed for PTCH1 in Gorlin syndrome patients. Although 
de novo mutations of the PTCH1 gene occur in almost 50% 
of Gorlin syndrome cases, there are a few recurrent muta-
tions. Our twin patients were carriers of a de novo mutation 
in the PTCH1 gene, c.3364_3365delAT (p.Met1122ValfsX22). 
This is, to our knowledge, the first Gorlin syndrome-caus-
ing mutation that has been reported four independent 
times in distant geographical locations. Therefore, we pro-
pose the location of the described mutation as a potential 
hot spot for mutations in PTCH1.
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Gorlin syndrome, or nevoid basal cell carcinoma syndrome 
(NBCCS), is a rare autosomal dominant disorder character-
ized by developmental abnormalities including cleft pal-
ate and skeletal abnormalities, such as bifid ribs, palmar 
and plantar pits, macrocephaly, and calcification of the falx 
cerebri, and a predisposition to the development of various 
tumors, such as basal cell carcinomas (BCCs), desmoplastic 
medulloblastomas, jaw cysts, and fibromas of the ovaries 
and heart, which occur at different ages (1). Although this 
disorder has almost complete penetrance, it is sometimes 
difficult to diagnose due to its highly variable features both 
within and outside families and very low estimated preva-
lence of only 1 in 57 000 to 1 in 256 000 persons (2,3).
This complex disorder is mostly caused by mutations of 
the Patched 1 (PTCH1) gene, although rare mutations of 
Patched 2 (PTCH2) or Suppressor of Fused (SUFU) genes 
have also been found (2). They are all members of the 
Hedgehog-Gli (Hh-Gli) signaling pathway, which is an im-
portant developmental pathway involved in body sym-
metry patterning and organ differentiation (2,4). It is also 
involved in patterning of steroidogenic tissues and sex 
determination during embryonic development (5). Hh-
Gli signaling pathway, which is normally active only dur-
ing embryonic development and in stem cells,  is inactive 
in adult differentiated tissues (6), becomes dysregulated 
and overly active in many different cancer types (7).
This report describes twins with sporadic Gorlin syndrome, 
with possibly the first truly recurrent PTCH1 mutation. One 
of the twins also had a rare tumor that might be a new Gor-
lin syndrome feature.
CASE REPORT
We present a case of monozygotic twins, born in 1981, 
with Gorlin syndrome. At age 11, the first twin presented 
with urinary tract infection with hematuria. During the ex-
amination, several pigmented moles on the patients’ skin, 
winged scapula (scapula alata), kyphosis, and funnel chest 
were noted. Relevant family history was taken, but the Gor-
lin syndrome was not suspected (Table 1). At age 13, he 
developed benign paratesticular mesothelioma. At age 17, 
when he developed the first multiple jaw cysts and only 
after his brother already been surgically treated for his jaw 
cyst at the same clinic, the Gorlin syndrome was suspected 
for both brothers. Eventually, they were diagnosed as spo-
radic cases.
Thorough medical exams were conducted and detailed 
family history was taken. The patient had calcification of 
the falx cerebri, bridging of sella turcica, hypoplasia of fron-
tal parts of the ribs VI and VII on the right front side, anterior 
open bite, partial hypoplasia of tooth enamel, multiple jaw 
keratocysts, and numerous nevoid skin changes.
The second brother had his first jaw cyst diagnosed at the 
age of 16, and multiple jaw cysts at the age of 17. He also 
had a slight calcification of the falx cerebri, calcification 
along the intraparietal suture and tabula interna of the 
frontal bone, deformity of left hemithorax, and several ne-
void skin changes.
Their mother had a thyroid tumor, liver and kidney cysts, 
and hypertension. Their father had several jaw cysts diag-
nosed several years before. One grandfather had jaw cysts 
TAbLE 1. Medical history timeline of both brothers. G1 – first patient, G2 – second patient.
G1 G2
Year








1992 (aged 11) Urinary tract infection 
with hematuria
Treated with antibiotics; Several 
nevi detected on the skin
1994 (aged 13) Benign paratesticular 
mesothelioma
Surgical removal
1997 (aged 16) Single jaw cyst Surgical removal
1998 (aged 17) Multiple jaw cysts Surgical removal, sporadic Gorlin 
syndrome suspected
Multiple jaw cysts Surgical removal, sporadic Gorlin 
syndrome suspected
2013 (aged 32) Multiple basal cell 
carcinomas (BCC)
Surgical excision of larger BCCs, 
cryotherapy for smaller, Gorlin 
syndrome diagnosed, Patched  
1 gene (PTCH1) testing indicated
Multiple basal cell 
carcinomas
Surgical excision of larger BCCs, 
cryotherapy for smaller, Gorlin 
syndrome diagnosed, PTCH1 testing 
indicated
2013 (aged 32) PTCH1 mutation 
testing




PTCH1 mutation found, Gorlin 
syndrome confirmed
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later in life (8). Other family members showed no relevant 
clinical features.
In 2013, at age 32, after both brothers developed multi-
ple basal cell carcinomas, Gorlin syndrome diagnosis was 
confirmed and additional tests were performed. The brain 
scan of the first brother showed cerebral lateral ventricu-
lar asymmetry, asymmetry of temporal horns, slight frontal 
cortical atrophy, and the radiographic images of the skel-
eton showed discrete thinning of the bone structure in the 
left femur, slight calcification of the right acetabulum, mild 
hypertrophy of the right femoral head-neck junction, and 
thinning of bone structure in the right thumb.
The second twin’s brain scan showed slight frontal cortical 
atrophy and the radiographic images of the skeleton de-
scribed discrete thinning of the bone structure in the distal 
third of both femurs and several bones of the right hand.
At that time, testing for PTCH1 gene mutations was rec-
ommended. The blood samples from both brothers, their 
parents, and their unaffected sister were obtained after 
signing informed consent forms. The study was conducted 
according to the Declaration of Helsinki principles.
Quantitative multiplex polymerase chain reaction (PCR) 
was used for the analysis of large rearrangements (9) and 
high-resolution melting analysis for point mutations (10), 
followed by sequencing in both directions. Quantitative 
multiplex PCR discovered a small deletion in exon 20 not 
present in either parent (Figure 1). Sequencing showed a 
PTCH1 mutation c.3364_3365delAT (p.Met1122ValfsX22), 
predicted to occur in the transmembrane domain 11. 
Since the mutation was absent in the parents, we want-
ed to determine whether the mutation occurred on the 
maternal or paternal allele. All 14 known polymorphisms 
previously found in Croatia were typed in both parents 
(Table 2). Only three polymorphisms were found. One 
was not informative, and while both c.1504-51C>G in in-
tron 10 and c.1647C>T in exon 12 differed in parents and 
sons, with more than 20 000 bp away from the mutation 
site, it was not possible to determine the strand of ori-
gin. The c.1647C>T polymorphism seems to be a very rare 
Croatian polymorphism, previously found in only a few 
samples (10).
TAbLE 2. Patched 1 gene (PTCH1) polymorphisms typed for linkage analysis in twins with Gorlin syndrome and their parents*
Polymorphism rs # F M G1 G2
c.-4_-3insGGC rs587780530 WT WT WT WT
c.202-538delC rs11362678 WT WT WT WT
c.318C>T rs1805153 WT WT WT WT
c.735A>G rs1805154 WT WT WT WT
c.747-55T>C rs2297087 WT WT WT WT
c.1504-51C>G rs574688 HO HET HET HET
c.1504-8T>C rs2277184 WT WT WT WT
c.1641C>T rs2066830 WT WT WT WT
c.1647C>T ss2137510529 WT HET HET HET
c.1665T>C rs1805155 WT WT WT WT
c.1686C>T rs2066836 WT WT WT WT
c.2560 + 9G>C rs2066829 WT WT WT WT
c.3141T>G rs2066835 WT WT WT WT
c.3944C>T rs357564 HET HET HO HO
*Abbreviations: rs # – a reference single nucleotide polymorphism identification (SNP ID) number, ss # – a submitted SNP ID number, M – mother, F – 
father, G1 – first patient, G2 – second patient, WT – wild type, HET – heterozygote, HO – rare homozygote.
FIGuRE 1. Quantitative multiplex polymerase chain reaction 
(PCR) analysis showing the deletion in exon 20 of Patched 1 
gene (PTCH1) seen as an extra peak in brothers (G1 and G2), 
whereas in the parents the extra peak is absent.
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Since 2013, both brothers have been under regular ob-
servations at the Dermatologic Surgery of the University 
Department of Dermatovenereology, University Hospital 
“Sestre milosrdnice” and have had multiple basal cell carci-
nomas removed on more than 20 occasions.
DISCuSSION
This report describes a case of twins with sporadic Gorlin 
syndrome. The patients are carriers of a de novo mutation 
in the PTCH1 gene, c.3364_3365delAT (p.Met1122ValfsX22). 
Both have common Gorlin syndrome features, but one 
brother also had benign testicular mesothelioma. We pro-
pose that this tumor type might be a possible new Gorlin 
syndrome feature.
Gorlin syndrome is a complex disease and rarely occur-
ring symptoms can easily be overlooked, especially during 
childhood, as was the case with the brothers’ first jaw cysts 
and skin nevi. The first brother has a more severe pheno-
type, even though they are monozygotic twins. This has 
been noted before for monozygotic twins affected by Gor-
lin syndrome, and has mostly been attributed to environ-
mental factors (11).
The first brother developed benign paratesticular meso-
thelioma, which is not an established Gorlin syndrome fea-
ture, but it might be of some interest. These tumors are 
rare, benign, and typically occur in men in their twenties 
to sixties (12). Malignant mesotheliomas can have muta-
tions in PTCH1, Smoothened (SMO), and SUFU genes (13). 
Mesotheliomas in both their benign and malignant forms 
are derived from the mesenchymal tissue, most often dur-
ing the development and differentiation of genital tract 
organs (14). Since the Hh-Gli pathway is involved in pat-
terning of steroidogenic tissues, it is not surprising to find 
this type of tumor in the Gorlin syndrome patient. Benign 
mesothelioma has likely not been associated with the syn-
drome before because it is rare and usually detected only 
incidentally.
The brothers were diagnosed as sporadic cases of Gorlin 
syndrome, because their parents do not have the consti-
tutive PTCH1 mutation. It is possible that the father has a 
mosaic mutation, since he has some features of Gorlin syn-
drome, but not the mutation in his constitutional DNA. Un-
fortunately, there was no tumor material available to test. 
De novo PTCH1 mutations are quite common, in up to 50% 
of patients, and the same mutation is rarely found twice 
(3). Interestingly, the mutation we describe here has been 
reported three times so far, in Australia and New Zealand 
(15), USA (3) and Japan (16). As in our patients, all cases 
were sporadic (personal communication for the USA and 
Japan patients). It is likely that the structure and the se-
quence of DNA at this position is a fragile site prone to 
damage and is more likely to be affected by random DNA 
damaging events.
Although founder PTCH1 mutations have not been de-
scribed in the literature, several recurrent mutations have 
been reported (17). Until this report, a recurrent mutation 
has been reported only three times and only in family cas-
es. Sporadic de novo mutations were only reported twice 
for each mutation.
This is, to our knowledge, the first mutation that is de-
scribed four times in very distant geographical locations, 
and at least three times as a sporadic mutation. Therefore, 
we would like to propose the c.3364_3365delAT mutation 
as a potential hot spot for mutations in PTCH1.
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